Q BioMed Treats its First Patient in Commercial Setting Following Product Launch

●     Full commercial launch expected in the coming weeks of March

●     An estimated 10 million people are living worldwide with pain from bone metastases

NEW YORK, March 12, 2020 - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company,  announced today the first patient has been dosed in a commercial setting with its U.S. FDA approved non-opioid drug Strontium89  (Strontium Chloride Sr-89 Injection, USP) for patients with pain from metastatic bone cancer.

The Company completed its initial commercial production run and shipment in February and is pleased to have dosed the first of what it expects to be thousands of patients in the coming years. Due to the opioid crisis, clinicians and patients are looking for pain management alternatives. Strontium89, which can be administered every 3 months, was shown in numerous clinical trials to relieve pain in over 70% of patients who received the treatment.

“With an estimated 10 million people living with bone metastases, we expect that even a small penetration in this market will have dramatic effects on QBioMed’s future. We believe this drug has a very important role to play as clinicians move toward proven non-opioid therapeutics for pain palliation for patients with painful bone metastases,” stated Q BioMed CEO Denis Corin.

Q BioMed plans to launch the drug in global markets, including Europe, in late 2020.

To learn more please visit www.Strontium89.com.

About Q BioMed Inc.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.